ARTICLE | Clinical News

CHMP recommends against PharmaMar's Aplidin for MM

December 22, 2017 12:13 AM UTC

EMA's CHMP recommended against approval of Aplidin plitidepsin from PharmaMar S.A. (Madrid:PHM) to treat relapsed or refractory multiple myeloma. The committee said it will publish more information on the opinion "shortly."

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) has rights to Aplidin in eight EU countries, including the U.K., under a 2014 deal (see BioCentury, Aug. 4, 2014)...